Claims

1. Use of an azolo compound (I)



I , wherein

R is selected from the group consisting of H, D, CN, NHR^5, NDR^5, Cl, OR^3, SR^3 and C_{1-4}-alkyl, in particular H, D, methyl;

X is N or CR^1, wherein the nitrogen or carbon atom is an aromatic atom;

W is selected from the group consisting of a covalent bond, CR^4, wherein the carbon atom is an aromatic ring atom, CH_2, S, O, N, wherein the nitrogen atom is an aromatic ring atom, NH and NR^2;

X^1 is selected from the group consisting of a covalent bond, CR^4, wherein the carbon atom is an aromatic ring atom, CH_2, S, O, N, wherein the nitrogen atom is an aromatic ring atom, NH and NR^2;

Y is selected from the group consisting of a covalent bond, CR^4, wherein the carbon atom is an aromatic ring atom, CH_2, S, O, N, wherein the nitrogen atom is an aromatic ring atom, NH and NR^2;

Z is selected from the group consisting of a covalent bond, CR^4, wherein the carbon atom is an aromatic ring atom, CH_2, S, O, N, wherein the nitrogen atom is an aromatic ring atom, NH and NR^2;

wherein ⋱ denotes a single bond or a double bond; wherein

W, X^1, Y and Z are members of the same ring and are selected such that the ring consists of five or six members;

W, X^1, Y and Z are selected such that the ring does not comprise more than two nitrogen atoms in the ring, and W, X^1, Y and Z are selected such that the ring does not comprise an acetal, thioacetal, aminal or hydrazine group;

wherein the compound does not comprise a peroxide or disulfide group; and wherein

R^1 is selected from the group consisting of H, D, CD_3, CHD_2, CH_2D, CF_3, CHF_2, CH_2F, CDF_2, CD_2F, C_{1-4}-alkyl, optionally substituted with OH, halogen, OR^3;

R^2 is selected from the group consisting of CHO, $COCH_3$, COC_2H_5, COC_3H_7, $COCH(CH_3)_2$, COC_4H_9, $COC(CH_3)_3$;

R^3 is selected from the group consisting of C_{1-4}-alkyl;

R^4 is selected from the group consisting of H, D, F, Cl, methyl, CH_2F, CHF_2, CF_3, OCH_3, OCD_3; and

R^5 is C_{1-4}-alkyl, optionally substituted with OH,

in the preparation of a medicament for the treatment or prevention of fibrosis.

2. The use according to claim 1, wherein R is selected from the group consisting of H, CN, NHR^5, Cl, OR^3, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl and SR^3.

3. The use according to claim 1 or claim 2, wherein R^1 is selected from the group consisting of H, D, CD_3, CHD_2, CH_2D, CF_3, CHF_2, CH_2F, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl and cyclopropyl, optionally substituted by OH, Halogen or OR^3, optionally, wherein R^1 is selected from the group consisting of H, methyl, CD_3, CF_3, CH_2OH, ethyl, CH_2OCH_3 and cyclopropyl,

and/or wherein R^3 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl,

and/or wherein R^5 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl, optionally substituted by OH.

4. The use according to any of claims 1 to 3, wherein W, X^1, Y and Z are selected such that the compound does not include a peroxide group and/or such that the compound does not include a disulfide group.

5. The use according to any of claims 1 to 4, wherein X is selected from the group consisting of N and CR^1 and wherein R^1 is selected from the group consisting of H, methyl, CH_2F, CD_2F, CHF_2, CDF_2, and CF_3, preferably, wherein X is CR^1 and R is H or D.

6. The use according to any of claims 1 to 5, wherein W, X^1, Y and Z are selected such that the ring consists of carbon atoms or such that the ring consists of carbon atoms and one heteroatom,

and/or wherein W, X^1, Y and Z are selected such that the ring is aromatic or non-aromatic.

7. The use according to any of claims 1 to 6 wherein W, X^1, Y and Z are selected to form a moiety according to one of the following ring atom sequence: C···C···C···C, N···C···C···C, C···N···C···C, C···C···N···C, C···C···C···N, S···C···C···C, C···S···C···C, C···C···S···C, C···C···C···S, O···C···C···C, C···O···C···C, C···C···O···C, C···C···C···O, C···C···C, N···C···C, C···N···C, C···C···N, S···C···C, C···S···C, C···C···S, , O···C···C, C···O···C, C···C···O, wherein "···" denotes a single bond or a double bond, and/or

wherein W, X^1, Y and Z are independently selected such that the ring forms a pyrrolidine, dihydrofuran, dihydrothiophen, pyrrole, furan, thiophene, oxazole, thiazole, tetrahydrobenzene, oxane, thiane, benzene, pyridine, pyran, thiopyran, preferably benzene, pyridine, dihydropyridine, thiophene or furan structure.

8. The use according to any one of claims 1 to 7, wherein W, X^1, Y and Z are independently selected to form a moiety selected from the group consisting of CH=CH-CH=CH, CH=N-CH=CH, N=CH-CH=CH, CH=CH-CH=N, NH-CH_2-CH_2-CH_2, CH_2-NH-CH_2=CH_2, CH_2-N$COCH_3$-CH_2-CH_2, S-CH=CH, CH=CH-S, CH-S-CH, CH=CH-O, preferably CH=CH-CH=CH or CH-S-CH.

9. The use according to any one of claims 1 to 8,

wherein W, X^1, Y and Z are selected to form the moiety CH=CH-CH=CH and wherein R = H and wherein X is N; or

wherein W, X^1, Y and Z are selected to form the moiety CH=CH-CH=CH and wherein R = H and wherein X is C-CH_3; or

wherein W, X^1, Y and Z are selected to form the moiety CH=CH-CH=CH and wherein R = H and wherein X is C-H; or

wherein W, X^1, Y and Z are selected to form the moiety CH-S-CH and wherein R = H and wherein X is C-CH_3; or

wherein W, X^1, Y and Z are selected to form the moiety CH-S-CH and wherein R = H and wherein X is N.

10. The use according to any one of claims 1 to 9, wherein X is C-CH_3, R is H, and W, X^1, Y and Z are forming the group $CR^4=CR^4-CR^4=CR^4$, wherein one R^4 group is selected from the group consisting of F, Cl and OCH_3 and wherein the remaining three R^4 groups are hydrogens.

11. The use according to any one of claims 1 to 10, wherein X is C-CH_3, R is H, and W, X^1, Y and Z are forming the group $CR^4=CR^4-CR^4=CR^4$, wherein two R^4 groups are independently selected from the group consisting of F, Cl and OCH_3 and wherein the remaining two R^4 groups are hydrogens.

12. The use according to any one of claims 1 to 11, wherein the azolo compound (I) is selected from the group consisting of:



1



2



3



4



5



6



7



8



9



10



11



12



13



14



15



16



17a



17b



18a



18b



19a



19b



20a



20b



21a



21b



22a



22b



23a



23b



24a



24b



25



26a



26b



27



28a



28b



29



30

31

32a

32b



33a



33b



34



35



36



37



38



39



40



41



42



43



44a



44b



45



46a



46b



47a



47b



48a



48b



49a



49b



50a



50b



51a



51b



52



53



54



55



56a



56b



57



58a



58b



59a



59b



60a



60b

61a

61b

62a

62b



33a



33b



34



35



36



37



38



39



40



41



42



43



44a



44b



45



46a



46b



47a



47b



48a



48b



49a



49b



50a



50b



51a



51b



52



53



54



55



56a



56b



57



58a



58b



59a



59b



60a



60b

61a

61b

62a

62b

, optionally, wherein the azolo compound (I) is selected from the group consisting of:



.

13. The use according to any of claims 1 to 12, wherein fibrosis is selected from the group consisting of kidney fibrosis, liver fibrosis, lung fibrosis and cardiac fibrosis, optionally cardiac fibrosis.

14. Use of a pharmaceutical composition comprising an azolo compound or a mixture of azolo compounds each having the structure (I)



I

as defined in claim 1 and a pharmaceutically acceptable carrier for the preparation of a medicament for the treatment of fibrosis.

15. The use according to claim 14, wherein the medicament is an oral solid dosage form and/or wherein the azolo compound is present in an amount of from 5 to 500 mg, preferably 10 to 200 mg.